All In Biotech

Free tool

FAERS Monitor: Tosymra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210884 or its brand name (Tosymra, Sumatriptan). Reports on generic versions are filed under their own applications.

Reports

18,395

Serious

11,313

62% of reports

Hospitalization

3,856

Death reported

585

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,839
  • headache1,501
  • migraine1,273
  • nausea1,260
  • fatigue1,073
  • dizziness887
  • pain851
  • off label use838
  • vomiting720
  • dyspnoea658
  • diarrhoea648
  • anxiety613
  • arthralgia502
  • depression498
  • malaise495

Reports by year received

View as table
YearReports
200416
200512
20062
20074
200820
200946
201083
2011100
2012334
2013371
2014554
2015790
20161,137
20171,168
20181,728
20191,878
20201,637
20211,524
20221,432
20231,642
20241,340
20251,445
20261,132

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,764 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
migraineSignal1,27315.414.617,025
headacheSignal1,5012.72.61,706
depressionSignal4982.52.3453
anxietySignal6132.52.3539
dizzinessSignal8872.01.9477
nausea1,2601.81.7484
vomiting7201.81.6237
drug ineffective1,8391.61.5436
pain8511.61.5188
fatigue1,0731.61.5234
arthralgia5021.41.353
dyspnoea6581.31.255
malaise4951.31.233
diarrhoea6481.11.113
off label use8381.11.07

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.